Escitalopram (Lexapro) for the Treatment of Postpartum Depression (LexaproPPD)

Mass General Brigham

Status and phase

Completed

Phase 4

Conditions

Postpartum Depression

Treatments

Drug: Escitalopram

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00833469

2008-P-001509

Details and patient eligibility

About

The purpose of this study is to determine whether women with postpartum major depressive disorder (MDD) will experience a significant decrease in depressive symptoms from baseline over an eight-week treatment intervention with escitalopram (Lexapro). Also, to determine whether women with postpartum MDD will experience a significant decrease in anxiety symptoms.

Enrollment

7 patients

Sex

Female

Ages

18 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Women ages 18 to 45 years old
Subjects must meet criteria for a major depressive episode with symptoms developing within three month of live childbirth
Subjects must present within six months of childbirth
MADRS score >15
BAI score >10
Subjects will be able to be treated on an outpatient basis
Subjects will be able to provide written informed consent

Exclusion criteria

Subjects who have taken any psychotropic medication, including antidepressants and anti-anxiety medication, within the past two weeks (with the exception of non-benzodiazepine medications used for sleep, including trazodone, zolpidem, eszopiclone, etc)
Suicidal ideation with active plan or intent, as determined by the investigator
Presence of psychotic symptoms or homicidal ideation
History of mania or hypomania
Pregnant or breastfeeding
Presence of chronic depression or dysthymia, or chronic or treatment resistant anxiety disorders, as determined by investigator
Active alcohol/substance abuse currently or within the past year
Abnormal TSH, severe anemia, or uncontrolled hypertension